Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Niclosamide in Healthy Adults
NCT05168644Phase 1Completed
- Sponsor
- TFF Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of niclosamide in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by TFF Pharmaceuticals. Primary endpoints: Adverse Events, Vital Sign Abnormalities and 4 more. Started Nov 2021; status: completed.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05168644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168644.